Regeneron Gets FDA Approval for EYLEA’s Pediatric Treatment
In another breakthrough for BCW Member Regeneron Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has approved the company’s EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, EYLEA is now indicated to treat five retinal conditions caused by ocular angiogenesis.
“Retinopathy of prematurity is a leading cause of childhood blindness worldwide. Until now, the only FDA-approved treatment in common use was laser photocoagulation, a complex and lengthy procedure that permanently ablates retina tissue and is stressful not only for infant patients but also the family navigating a delicate time after a preterm birth,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, and a principal inventor of EYLEA. “For the first time, physicians will now have an FDA approved medication in EYLEA to treat this heartbreaking disease in these smallest of patients. We thank the investigators and the many families who participated in the clinical trials.”
Each year in the U.S., between 1,100 to 1,500 infants develop ROP that is severe enough to require medical treatment. This rare eye disease often impacts infants who are born before 31 weeks of pregnancy have been completed or who weigh less than 3.3 lbs pounds at birth. “Regeneron’s trials investigating EYLEA in retinopathy of prematurity have advanced our understanding of how to treat this disease and provided a needed evidence-based treatment option to potentially help preterm infants preserve their vision,” said Jeff Todd, Chief Executive Officer of Prevent Blindness.
EYLEA is being jointly developed by Regeneron and Bayer.
Similar News Items
BCW Member Northwell Health is going to be the lead sponsor of the professional soccer team that is going to make its home at Mount Vernon’s Memorial Field, according to an announcement from BCW Member Westchester Soccer Club (WSC), a new USL League One franchise. Northwell has committed to the sponsorship for the club’s inaugural […]
BCW Westchester Innovation Network participant Laronix held a showcase Wednesday to demonstrate its MIRA Voice device that uses artificial intelligence to help people with spinal cord injuries, cerebral palsy and other conditions regain the ability to speak clearly. The event at Serendipity Labs in White Plains welcomed medical professionals and others curious about MIRA Voice […]
Congratulations to BCW Member Westchester Medical Center Health Network (WMCHealth) on the groundbreaking Wednesday to commemorate the start of construction of the Critical Care Tower at Westchester Medical Center, a $220 million project that will span 162,000 square feet and rise five stories when complete. Located adjacent to Westchester Medical Center’s Main Tower, the Critical […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.